• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Colorectal cancer screening with fecal immunochemical testing: a community-based, cross-sectional study in average-risk individuals in Nigeria
This study aimed to assess the fecal immunochemical test as a colorectal cancer screening modality in average-risk individualS in Nigeria.METHODS: A population-based, cross-sectional study of qualitative fecal immunochemical test-based colorectal cancer screening was done in asymptomatic, average-risk participants aged 45-75 years in three states in Nigeria (Osun, Kwara, and Lagos). Participants were invited to enrol using age-stratified and sex-stratified convenience sampling following community outreach. Exclusion criteria included a personal history of colorectal cancer or rectal bleeding in the previous 6 months, a fir...
Source: Cancer Control - June 17, 2022 Category: Cancer & Oncology Authors: Olusegun I Alatise Anna J Dare Patrick A Akinyemi Fatimah B Abdulkareem Samuel A Olatoke Gregory C Knapp T Peter Kingham African Research for Oncology Colorectal Screening Early Detection Group Source Type: research

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

Tenure-track or tenure-eligible investigator in biomedical image processing
The National Library of Medicine (NLM), a component of the National Institutes of Health (NIH) and the Department of Health and Human Services (DHHS), is recruiting for a tenure-track or tenure-eligible investigator within its Intramural Research Program (IRP) in Bethesda, MD. The recruitment is part of a planned expansion of NLM ’s intramural research in computational health sciences. The goal of this search is to identify candidates with the potential to develop a dynamic, innovative, and independent research program with a focus on clinical image processing (e.g., radiology, pathology, endoscopy).
Source: NLM General Announcements - September 14, 2020 Category: Databases & Libraries Source Type: news

Renaissance Radiologists: Meet AJ Gunn, MD
AJ Gunn, M.D. graduated magna cum laude from Brigham Young University in Provo, UT, earning a BS in exercise physiology with a minor in sociology. He then returned home to South Dakota to attend medical school at the University of South Dakota. During medical school, he participated in the competitive Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program and was awarded the Donald L. Alcott, M.D. Award for Clinical Promise. He graduated summa cum laude in 2009. He completed his diagnostic radiology residency at the Massachusetts General Hospital of Harvard Medical School in Boston, MA ...
Source: radRounds - February 21, 2020 Category: Radiology Authors: Robin Pine Miles Source Type: blogs

Renaissance Rad Feature: Meet AJ Gunn, MD
AJ Gunn, M.D. graduated magna cum laude from Brigham Young University in Provo, UT, earning a BS in exercise physiology with a minor in sociology. He then returned home to South Dakota to attend medical school at the University of South Dakota. During medical school, he participated in the competitive Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program and was awarded the Donald L. Alcott, M.D. Award for Clinical Promise. He graduated summa cum laude in 2009. He completed his diagnostic radiology residency at the Massachusetts General Hospital of Harvard Medical School in Boston, MA ...
Source: radRounds - February 21, 2020 Category: Radiology Authors: Robin Pine Miles Source Type: blogs